
|Articles|January 1, 2003
Systemic retinoid chemoprophylaxis causes frequent adverse events for immunosuppressed transplant patients with advanced SCC
Chicago -- Although published clinical trial results suggest systemic retinoid therapy administered for skin cancer chemoprevention in immunosuppressed organ transplant recipients is well tolerated despite causing frequent adverse events,
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5


















